Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs TransMedics Group Inc (TMDX) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs TransMedics Group Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $20.18, while TransMedics Group Inc trades at $75.76 (market cap $2.58B). The key difference: TransMedics Group Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

CONYTMDX
Sector
Income / Options OverlayTechnology
52-Week High
$103.20$150.42
52-Week Low
$18.43$61.99
Market Cap
$2.58B
Enterprise Value
$2.98B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.

The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.

TransMedics Group Inc

TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.

The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.

Returns comparison

Trailing returns across standard periods

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX